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Developing a rigorous basic science 
foundation was the primary focus of 
Irwin Freedberg’s vision for dermatol-
ogy. When I was a student working in 
Irwin’s lab at Johns Hopkins University, 
his dedication to the scientific under-
pinnings of dermatology expanded my 
own view of the field. The explosion in 
our scientific understanding of the skin 
during Irwin’s career as a basic scientist 
and as an advocate for basic science has 
been a remarkable achievement.
But dermatology underwent several 
other major transformations during the 
span of Irwin’s career. There has also 
been an expansion in the surgical and 
cosmetic aspects of the field. We have 
lost venereology to infectious diseases, 
a subspecialty of internal medicine. As I 
describe below in more detail, we may 
be losing cutaneous autoimmune diseas-
es to rheumatology, another subspecialty 
of internal medicine. Recently, we have 
gained a significant epidemiologic effort.
The urgent issue in Irwin’s day was 
how to make dermatology a solid, 
respectable field capable of intellec-
tual growth, and his answer was basic 
scientific rigor. The urgent issue today, 
in my opinion, is how to translate sci-
entific advances from dermatology 
and other fields into improved care for 
patients with skin disease. The recent 
epidemiologic efforts have worked well 
for common dermatologic diseases, 
such as psoriasis and skin cancers, but 
there are many complex dermatologic 
diseases that are not represented in suf-
ficient numbers in available epidemio-
logic databases. These diseases include 
cutaneous lupus erythematosus, der-
matomyositis, and autoimmune blister-
ing diseases, among others — diseases 
in which there are significant systemic 
manifestations and/or the need to use 
powerful medicines with significant sys-
temic side effects. These conditions fall 
within medical dermatology, a branch 
of dermatology that requires of its prac-
titioners a substantial familiarity with 
internal medicine.
In an effort to advocate for medi-
cal dermatologists and their patients, 
we formed the Medical Dermatology 
Society ten years ago (Sontheimer et 
al., 1996). The overarching goal of the 
group is to keep medical dermatology 
within dermatology, to stop its piece-
meal removal into other subspecialties 
of internal medicine where cutane-
ous expertise is slight (Sontheimer et 
al., 1996). Our advocacy has included 
testifying to a subcommittee of the 
Department of Health and Human 
Services about the impact of federal 
policies on medical dermatology in 
academic medical centers (Sontheimer 
and Werth, 1998). Throughout all of 
medicine, not just dermatology, the 
cognitive specialties and subspecialties 
have suffered for many years (Werth et 
al., 1998). Medical dermatology suf-
fered a heavy blow when the govern-
ment stopped paying for a second resi-
dency for an individual; this, in many 
situations, forces us to select applicants 
who complete no more than one year 
of internal medicine training. Another 
blow was the tightening of clinical 
reimbursements, which pushed faculty 
away from patients with complex medi-
cal dermatologic problems. It’s hard to 
cover your salary when each patient 
takes so much time. Many academic 
dermatologists who had a primary 
focus on complex medical dermatol-
ogy dropped out of full-time academ-
ic medicine. Irwin made passionate 
contributions as a coauthor of a “case 
report” that documented the difficulties 
experienced by one medical derma-
tologist (Werth et al., 2001). Irwin built 
an in-patient dermatology service, even 
making a site visit to the University of 
Miami to see its very successful service, 
but experienced firsthand at his own 
institution the difficulties of sustaining 
individuals committed to in-patient and 
complex medical dermatology.
Other fields facing similar problems 
have built foundations to fund different 
types of research, including transla-
tional and patient-oriented research. In 
rheumatology, the Alliance for Lupus 
Research and the Lupus Research 
Institute have funded millions of dol-
lars’ worth of research and have tried 
to focus funding in areas traditionally 
not funded by the National Institutes 
of Health. They have evolved new pri-
vate sources of funding that have pro-
vided the seed money to develop and 
sustain people in academic careers, as 
well as to fund trial infrastructure at 30 
lupus centers so they would be well 
positioned when trials became avail-
able. Those centers can now also per-
form more mechanistic work related 
to those trials to further evaluate thera-
pies. Without a diversity of individu-
als to see patients with complex dis-
eases, teach, and do patient-oriented 
and translational research, it is hard to 
develop and mentor the next genera-
tion in those areas. We are now con-
fronted with that reality.
Developments have occurred over 
the past five years that will have excit-
ing implications for the future of 
medical dermatology. There are men-
toring awards through the Medical 
Dermatology Society and the Women’s 
Dermatologic Society to fund electives 
focused on medical dermatology for 
dermatology residents. There is now 
a thriving combined internal medi-
cine–dermatology program at several 
institutions in the United States. These 
are attracting new residents who might 
otherwise have chosen other fields in 
internal medicine. The Dermatology 
Foundation now has a Medical 
Dermatology Career Development 
Award to protect people’s time as they 
start their academic careers. This award 
will allow individuals to become com-
petitive for National Institutes of Health 
funding mechanisms for patient-orient-
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ed and translational research. Some of 
these K23 (early) and K24 (mid-career) 
grants have made a large difference in 
sustaining individuals in their academic 
careers. The Veterans Administration 
has long recognized the need for trans-
lational and outcomes research in their 
funding mechanisms.
We are in the early years of a revolu-
tion in the therapies that will be avail-
able in medical dermatology. We have 
already seen the impact of new drug 
development on psoriasis and cuta-
neous T-cell lymphoma. With many 
new immunomodulatory drugs in the 
pipeline, our challenge is to fund the 
infrastructure that will allow studies of 
other diseases in medical dermatology. 
This requires funding to protect the 
time that people spend in academics 
so they can not only care for patients 
with complex diseases but advance 
the field with the clinical and trans-
lational studies needed to evaluate 
these new therapies. There is so much 
exciting work to be done, and if we 
capture these opportunities, it will sus-
tain and develop these aspects of our 
field. Opportunities to go from bench 
to bedside research are clear, but there 
are opportunities to go from bedside to 
bench that will require individuals with 
a true commitment to caring for those 
with dermatologic diseases to gather 
the insights that will stimulate further 
basic discoveries (Holcombe, 2005). 
We need to develop a broader work 
force in medical dermatology whose 
members are sustained over a lifetime 
of contributions. Those who choose 
cognitive careers must be given the 
time to exercise creativity and advance 
the field. The benefits to our field and 
our patients will be obvious, and if the 
opportunities are there, we will have 
no trouble attracting a new generation.
What do we need to do for the 
future? We need more funding models 
to sustain our academic work force in 
the area of medical dermatology. This 
can be done through private founda-
tions, endowed chairs, and increased 
governmental grant support. We need 
funding to link centers together to sys-
tematically study our less common dis-
eases. At a time when there is potential 
pharmaceutical interest of importance 
to our patients and our field, we lack 
outcome measures and expertise in 
many diseases. We risk losing our dis-
eases to other fields if we don’t quickly 
address these issues. The lack of out-
come measures in cutaneous lupus 
erythematosus was recently addressed, 
but the new tools will not be used in 
dermatology without development of 
more dermatology centers with both 
clinical expertise and the ability to 
perform trials (Albrecht et al., 2005). 
Our combined med–derm programs 
will, with the requisite interdigitation 
of training, build bridges to other fields 
that will allow us to interface more 
effectively. We need to develop and 
maintain a prominent place within the 
academic hospital. This requires car-
ing for sicker patients; having residents 
who are properly trained and inter-
ested in providing necessary in-patient 
coverage; and renewing our commit-
ment to this important component of 
our field. This particular goal will not 
be achieved easily and will require a 
critical mass of dedicated individuals 
that we now lack. The idea of short-
term return on investment — what 
medical centers frequently want to 
see for allocation of funds — will not 
work, and we need creative develop-
ment of new forms of funding.
Many young people are entering 
dermatology who would be thrilled at 
the opportunity to rebuild medical der-
matology. We need to provide them, 
and their future patients, with the 
opportunities to succeed. I am sure that 
Irwin, had he not experienced such an 
untimely death, would have continued 
to champion this important aspect of 
our field.
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Absolutely no one cared more about 
the future of dermatology than Irwin 
Freedberg. He passionately worried, 
fretted, cajoled, exhorted, and inspired 
us to be mindful of the changes affect-
ing our field and those that will affect 
us for years to come. Many knew 
Irwin as a scientist, a chairman, and 
an organizational leader, but his eyes 
also lit up as he thought about the 
types of people who would be prac-
ticing dermatology in the future, the 
survival of the institutions where they 
would train, the types of practices they 
would create, and their relation to the 
communities in which they worked.
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